Artivion, Inc. (NYSE:AORT) VP Sells $228,540.00 in Stock

Artivion, Inc. (NYSE:AORT) VP Andrew M. Green sold 7,618 shares of Artivion stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total value of $228,540.00. Following the transaction, the vice president now directly owns 33,503 shares of the company’s stock, valued at approximately $1,005,090. This represents a 18.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Artivion Price Performance

Shares of AORT stock opened at $29.65 on Thursday. Artivion, Inc. has a 12-month low of $16.48 and a 12-month high of $30.10. The business has a 50 day simple moving average of $27.26 and a 200 day simple moving average of $25.93. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33.

Hedge Funds Weigh In On Artivion

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company boosted its stake in Artivion by 3.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,301 shares of the company’s stock valued at $392,000 after purchasing an additional 481 shares in the last quarter. Louisiana State Employees Retirement System lifted its position in shares of Artivion by 3.1% during the 2nd quarter. Louisiana State Employees Retirement System now owns 19,900 shares of the company’s stock valued at $510,000 after acquiring an additional 600 shares during the last quarter. Intech Investment Management LLC lifted its position in shares of Artivion by 6.6% during the 3rd quarter. Intech Investment Management LLC now owns 10,530 shares of the company’s stock valued at $280,000 after acquiring an additional 653 shares during the last quarter. Quarry LP lifted its position in shares of Artivion by 210.8% during the 3rd quarter. Quarry LP now owns 1,209 shares of the company’s stock valued at $32,000 after acquiring an additional 820 shares during the last quarter. Finally, nVerses Capital LLC acquired a new stake in shares of Artivion during the 2nd quarter valued at $28,000. 86.37% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on AORT shares. Needham & Company LLC reissued a “buy” rating and issued a $30.00 price target on shares of Artivion in a report on Friday, September 27th. JMP Securities initiated coverage on Artivion in a research report on Wednesday, October 23rd. They set an “outperform” rating and a $33.00 price target for the company. Oppenheimer boosted their price target on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Finally, Stifel Nicolaus boosted their price objective on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, September 13th. Five analysts have rated the stock with a buy rating, According to MarketBeat, Artivion has a consensus rating of “Buy” and an average target price of $31.00.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.